Last reviewed · How we verify
Fast-acting insulin aspart — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Fast-acting insulin aspart (Fast-acting insulin aspart) — Aristotle University Of Thessaloniki.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fast-acting insulin aspart TARGET | Fast-acting insulin aspart | Aristotle University Of Thessaloniki | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fast-acting insulin aspart CI watch — RSS
- Fast-acting insulin aspart CI watch — Atom
- Fast-acting insulin aspart CI watch — JSON
- Fast-acting insulin aspart alone — RSS
Cite this brief
Drug Landscape (2026). Fast-acting insulin aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/fast-acting-insulin-aspart. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab